This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Donepezil provides greater benefits in mild compared to moderate Alzheimer’s disease: implications for early diagnosis and treatment


Molinuevo, J. L., Berthier, M. L., Rami, L.


Archives Of Gerontology And Geriatrics, Volume: 52, No.: 1, Pages.: 18-22

Year of Publication



We assessed the cognitive and functional outcomes of donepezil treatment in mild versus moderate Alzheimer’s disease (AD) patients. We performed a 6-month prospective, observational, multicenter study of the progression of cognitive and functionality abilities in a large sample patients with AD who initiated treatment with donepezil in monotherapy. According to baseline mini mental state examination (MMSE), patients were divided in two groups: mild AD (MMSE ≥ 21) and moderate AD (MMSE <21). Patients were evaluated with the memory alteration test (M@T) and the Alzheimer's disease functional assessment and change scale (ADFACS) at baseline and at 6 months. A total of 403 patients finished the study (mild AD=152; moderate AD=251). The MMSE total score and M@T score remained stable at 6 months in the whole sample, with MMSE memory domain and M@T free and cued recall domains improving significantly from baseline. Total ADFACS, instrumental (IADL) and basic activities of daily living (BADL) got significantly worse, with the worsening being significantly greater in the moderate AD group. Significant differences between the groups favoring mild AD were observed for MMSE memory, orientation and language domains, M@T temporal orientation and semantic memory domains, and for IADL. We concluded that in AD patients on donepezil, cognition remains stable at 6 months. The beneficial effect of donepezil treatment, in terms of cognition and functionality, is greater for mild than for moderate AD.; Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Bibtex Citation

@article{Molinuevo_2011, doi = {10.1016/j.archger.2009.11.004}, url = {}, year = 2011, month = {jan}, publisher = {Elsevier {BV}}, volume = {52}, number = {1}, pages = {18--22}, author = {J.L. Molinuevo and M.L. Berthier and L. Rami}, title = {Donepezil provides greater benefits in mild compared to moderate Alzheimer{textquotesingle}s disease: Implications for early diagnosis and treatment}, journal = {Archives of Gerontology and Geriatrics} }


activities of daily living, aged, alzheimer disease, cognition, diagnosis, disease progression, donezepil, drug effects, drug therapy, early diagnosis, female, humans, indans, male, memory, neuropsychological tests, nootropic agents, piperidines, prospective studies, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study

Type of Outcomes

ADLs/IADLs, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime